[go: up one dir, main page]

PH12017500400A1 - Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl) -3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol - Google Patents

Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl) -3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol

Info

Publication number
PH12017500400A1
PH12017500400A1 PH12017500400A PH12017500400A PH12017500400A1 PH 12017500400 A1 PH12017500400 A1 PH 12017500400A1 PH 12017500400 A PH12017500400 A PH 12017500400A PH 12017500400 A PH12017500400 A PH 12017500400A PH 12017500400 A1 PH12017500400 A1 PH 12017500400A1
Authority
PH
Philippines
Prior art keywords
oxopropane
methylpyrrolidin
azetidin
methylpyridin
oxy
Prior art date
Application number
PH12017500400A
Inventor
Ping Huang
Seth Dietrich Ribe
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH12017500400A1 publication Critical patent/PH12017500400A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides crystalline (2S)-3-[(3S,4S)-3-[(1R)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol, and pharmaceutical compositions thereof. The invention further provides methods of using this compound to treat overactive bladder.
PH12017500400A 2014-09-04 2017-03-03 Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl) -3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol PH12017500400A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/085925 WO2016033776A1 (en) 2014-09-04 2014-09-04 Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
PCT/US2015/047415 WO2016036596A1 (en) 2014-09-04 2015-08-28 Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl) -3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol

Publications (1)

Publication Number Publication Date
PH12017500400A1 true PH12017500400A1 (en) 2017-07-17

Family

ID=54073019

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017500400A PH12017500400A1 (en) 2014-09-04 2017-03-03 Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl) -3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol

Country Status (26)

Country Link
US (1) US10065942B2 (en)
EP (1) EP3189044B1 (en)
JP (1) JP6364545B2 (en)
KR (1) KR20170038884A (en)
CN (1) CN107001327B (en)
AP (1) AP2017009774A0 (en)
AU (1) AU2015312229B2 (en)
BR (1) BR112017003010A2 (en)
CA (1) CA2956517A1 (en)
CL (1) CL2017000467A1 (en)
CO (1) CO2017001097A2 (en)
CR (1) CR20170051A (en)
DO (1) DOP2017000037A (en)
EA (1) EA031089B1 (en)
EC (1) ECSP17013015A (en)
ES (1) ES2688167T3 (en)
IL (1) IL250356A0 (en)
MA (1) MA40606A (en)
MX (1) MX2017002688A (en)
NZ (1) NZ728359A (en)
PE (1) PE20170442A1 (en)
PH (1) PH12017500400A1 (en)
SG (1) SG11201701608RA (en)
TN (1) TN2017000045A1 (en)
TW (1) TWI570119B (en)
WO (2) WO2016033776A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201625591A (en) * 2014-09-12 2016-07-16 美國禮來大藥廠 Azetidinyloxyphenylpyrrolidine compounds
CN112409333B (en) * 2019-08-23 2024-06-14 武汉人福创新药物研发中心有限公司 Phenylpyrrolidine compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
AU2005295350A1 (en) * 2004-10-20 2006-04-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
SG166106A1 (en) 2005-09-29 2010-11-29 Bayer Schering Pharma Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
TWI617553B (en) * 2013-03-13 2018-03-11 美國禮來大藥廠 Azetidinyloxyphenylpyrrolidine compound

Also Published As

Publication number Publication date
CL2017000467A1 (en) 2017-10-20
US20170233373A1 (en) 2017-08-17
WO2016036596A1 (en) 2016-03-10
MX2017002688A (en) 2017-05-30
AP2017009774A0 (en) 2017-02-28
IL250356A0 (en) 2017-03-30
EP3189044A1 (en) 2017-07-12
ES2688167T3 (en) 2018-10-31
JP2017525747A (en) 2017-09-07
AU2015312229A1 (en) 2017-02-02
CN107001327A (en) 2017-08-01
CO2017001097A2 (en) 2017-04-28
ECSP17013015A (en) 2018-03-31
TW201619149A (en) 2016-06-01
EA201790143A1 (en) 2017-06-30
PE20170442A1 (en) 2017-04-26
AU2015312229B2 (en) 2017-11-16
NZ728359A (en) 2018-08-31
CA2956517A1 (en) 2016-03-10
EA031089B1 (en) 2018-11-30
CR20170051A (en) 2017-04-26
MA40606A (en) 2016-03-10
DOP2017000037A (en) 2017-02-28
TWI570119B (en) 2017-02-11
SG11201701608RA (en) 2017-03-30
KR20170038884A (en) 2017-04-07
US10065942B2 (en) 2018-09-04
TN2017000045A1 (en) 2018-07-04
CN107001327B (en) 2022-09-02
EP3189044B1 (en) 2018-08-01
WO2016033776A1 (en) 2016-03-10
BR112017003010A2 (en) 2017-12-12
JP6364545B2 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
MX2021015102A (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2018001890A (en) Bicyclic compounds as atx inhibitors.
DK3154959T3 (en) 1 - ((3S, 4R) -4- (3-fluorophenyl) -1- (2-methoxyethyl) pyrrolidin-3-yl) -3- (4-methyl-3- (2-methyl-pyrimidin-5-yl) - 1-PHENYL-1H-PYRAZOL-5-YL) URINE AS A TRKA-KINASE INHIBITOR
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
EP3233809A4 (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
AU2015352440B2 (en) Compounds
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX367519B (en) Triazole compounds as t-type calcium channel blockers.
MX2016016840A (en) Pyrazolyl-triazolyl-pyridines as pest-control agents.
PH12017500400A1 (en) Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl) -3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol
EP3104712A4 (en) Improved process for the synthesis of substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones
AU2014232502A8 (en) Process for the preparation of 4-amino-1-((1S,4R, 5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one
WO2012173504A3 (en) Method for synthesis of the substituted azetidinones and intermediates for their synthesis
ZA201700527B (en) Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl) -3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol
EP3114112A4 (en) Crystalline derivatives of (s)-1-((2r,3r,4s,5s)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol
EP3206683A4 (en) Novel methods, compounds, and compositions for anesthesia
PH12018500406A1 (en) Bicyclic compounds as atx inhibitors
PH12018500407A1 (en) New bicyclic compounds as dual atx/ca inhibitors
WO2017049140A3 (en) Angiotensin (1-7) analogs and methods relating thereto
MX2016009250A (en) Imidazoles for the treatment and prophylaxis of respiratory syncytial virus infection.